BRISBANE, Australia, April 28, 2020 /PRNewswire/ — Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020).

QBiotic’s STELFONTA now available

STELFONTA® (tigilanol tiglate) is now available as the first pharmaceutical treatment for all grades of canine non-metastatic mast cell tumours (MCT).[1]  MCTs are the second most frequent cancer diagnosed in dogs and the most common skin cancer, accounting for up to 21% of skin cancer cases.[2]

QBiotics have partnered with global veterinary pharmaceutical company, Virbac for marketing and distribution of STELFONTA® in the USA and Europe. The exclusive online Oncology Summit attracted over 300 veterinary oncologists and global opinion leaders. An